BR112023002608A2 - Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade - Google Patents
Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedadeInfo
- Publication number
- BR112023002608A2 BR112023002608A2 BR112023002608A BR112023002608A BR112023002608A2 BR 112023002608 A2 BR112023002608 A2 BR 112023002608A2 BR 112023002608 A BR112023002608 A BR 112023002608A BR 112023002608 A BR112023002608 A BR 112023002608A BR 112023002608 A2 BR112023002608 A2 BR 112023002608A2
- Authority
- BR
- Brazil
- Prior art keywords
- exendin
- satiity
- obesity
- enhancement
- treatment
- Prior art date
Links
- 108010011459 Exenatide Proteins 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA202070526 | 2020-08-12 | ||
| PCT/EP2021/072251 WO2022034062A1 (en) | 2020-08-12 | 2021-08-10 | Exendin-4 peptide analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002608A2 true BR112023002608A2 (pt) | 2023-05-09 |
Family
ID=80246995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002608A BR112023002608A2 (pt) | 2020-08-12 | 2021-08-10 | Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230303640A1 (https=) |
| EP (1) | EP4196495A1 (https=) |
| JP (1) | JP2023538871A (https=) |
| CN (1) | CN116390938A (https=) |
| AU (1) | AU2021324066A1 (https=) |
| BR (1) | BR112023002608A2 (https=) |
| CA (1) | CA3190959A1 (https=) |
| WO (1) | WO2022034062A1 (https=) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| NZ506839A (en) | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2004005342A1 (en) * | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
| CN101273059B (zh) | 2005-08-26 | 2014-02-19 | 艾伯维有限公司 | 治疗活性的α-MSH类似物 |
| BRPI0820535B8 (pt) * | 2007-11-16 | 2021-05-25 | Novo Nordisk As | composições farmacêuticas contendo insulina e um peptídeo insulinotrópico |
| EP2714069A4 (en) * | 2011-05-25 | 2015-06-24 | Amylin Pharmaceuticals Llc | LONG-TERM CONJUGATES WITH TWO HORMONES |
| RU2668791C2 (ru) | 2012-10-19 | 2018-10-02 | ТиЭксПи ФАРМА ГМБХ | АНАЛОГИ АЛЬФА- и ГАММА-MSH |
| AU2013366692B2 (en) * | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| JP2017513875A (ja) * | 2014-04-22 | 2017-06-01 | ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 分枝状アミノ酸プローブを有するペプチド類似体 |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
-
2021
- 2021-08-10 WO PCT/EP2021/072251 patent/WO2022034062A1/en not_active Ceased
- 2021-08-10 AU AU2021324066A patent/AU2021324066A1/en active Pending
- 2021-08-10 JP JP2023510345A patent/JP2023538871A/ja active Pending
- 2021-08-10 CA CA3190959A patent/CA3190959A1/en active Pending
- 2021-08-10 BR BR112023002608A patent/BR112023002608A2/pt unknown
- 2021-08-10 US US18/020,813 patent/US20230303640A1/en active Pending
- 2021-08-10 CN CN202180069840.1A patent/CN116390938A/zh active Pending
- 2021-08-10 EP EP21766122.2A patent/EP4196495A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021324066A9 (en) | 2023-04-27 |
| US20230303640A1 (en) | 2023-09-28 |
| WO2022034062A1 (en) | 2022-02-17 |
| CA3190959A1 (en) | 2022-02-17 |
| CN116390938A (zh) | 2023-07-04 |
| EP4196495A1 (en) | 2023-06-21 |
| AU2021324066A1 (en) | 2023-03-30 |
| JP2023538871A (ja) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017430A2 (pt) | Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos | |
| BR112019010699A2 (pt) | receptores de células t e imunoterapia empregando os mesmos | |
| AR111122A1 (es) | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro | |
| Guo et al. | Hydrogen sulfide as an endogenous modulator in mitochondria and mitochondria dysfunction | |
| BR112021021318A2 (pt) | Sapato funcional fácil de usar | |
| BR112021015832A2 (pt) | Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos | |
| NO20092774L (no) | HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
| BR112019009133A2 (pt) | vacina contra o parvovírus suíno | |
| BRPI0717098B8 (pt) | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação | |
| BR112016029713A2 (pt) | métodos para o tratamento de sobrepeso ou obesidade | |
| BR112018075396A2 (pt) | anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika | |
| BR112022005757A2 (pt) | Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| EA200900373A1 (ru) | Реконструированные сурфактанты, обладающие улучшенными свойствами | |
| BR112022024662A2 (pt) | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 | |
| BR112022014844A2 (pt) | Tratamento de doenças associadas ao panx1 | |
| BRPI0515857A (pt) | conjugados do fator-i de crescimento semelhante à insulina ( igf-i ) e polietileno glicol | |
| EA201990479A1 (ru) | Сульфонамиды в качестве агонистов gpr40 и gpr120 | |
| BR112023002608A2 (pt) | Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade | |
| BR112018068414A2 (pt) | derivados de ácido a-truxílico e composições farmacêuticas dos mesmos | |
| Wang et al. | Peptides from Antarctic krill (Euphausia superba) ameliorate acute liver injury in mice induced by carbon tetrachloride via activating the Nrf2/HO-1 pathway | |
| BR112023019984A2 (pt) | Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho | |
| Bhattacharjee et al. | L-DOPA treatment in MPTP-mouse model of Parkinson’s disease potentiates homocysteine accumulation in substantia nigra |